Biogen’s Tau Drug Slows Alzheimer’s Decline 38% at Two Years, as Real-World Leqembi Data Show 76% Fewer Patients Reaching Moderate Dementia

Biogen’s experimental tau drug diranersen slowed Alzheimer’s decline by 38% at two years, while new real-world Leqembi data showed a 76% lower rate of progression to moderate or severe dementia. Here is what the CTAD 2026 results mean, and their limits.

Read more